Hematology & Blood Cancer
Hematology & Blood Cancer
Advertisement
Cancer Nursing Today EditorsMultiple Myeloma | September 22, 2023
Although oral chemotherapy is convenient, adherence and safety must be monitored, especially in older patients.
Read More
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | August 11, 2023
Infection, pain, and psychological distress can all adversely affect this patient population. What can be done?
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | August 11, 2023
Disability leave, loss of income, and poor career opportunities were all challenges for patients with chronic GVHD.
Dustin SamplesGVHD | August 11, 2023
Enteral probiotics and prebiotics, along with vitamin D supplementation, may help prevent gut GVHD in AHSCT patients.
Dustin SamplesGVHD | August 11, 2023
The treatment reduced the risk of aGVHD and cGVHD but did not improve non-relapse mortality or overall survival.
Dustin SamplesMultiple Myeloma | July 31, 2023
Using carfilzomib instead of bortezomib improved progression-free and overall survival and reduced toxicity.
Dustin SamplesMultiple Myeloma | July 31, 2023
The difference was significant, with patients who received AHSCT with residual clonal plasma cells having much lower OS.
Dustin SamplesMultiple Myeloma | July 31, 2023
Though attrition rates increased, they were lower than previously reported.
Olivia ThomasMultiple Myeloma | July 26, 2023
Four themes were identified from patient telephone interview responses that summarized the experience of living with MM.
Dustin SamplesConferences | April 27, 2023
Accelerated approvals will no longer be granted based on overall response rates in single-arm trials.
Dustin SamplesConferences | April 6, 2023
The approved dosing schedule for venetoclax is time-limited, but how many patients follow the schedule?
Dustin SamplesConferences | April 6, 2023
Though rare, CLL and CML sometimes occur sequentially or concurrently. But what is the mechanism behind the relationship?
Dustin SamplesConferences | April 6, 2023
In a currently enrolling trial, patients with CLL and NMSC will receive experimental treatment with nicotinamide.
Dustin SamplesConferences | April 6, 2023
Deborah Stephens, DO, presented the recommendations and algorithms for first-, second-, and third-line CLL/SLL therapy.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | March 29, 2023
Graft-versus-host disease is the most life-threatening consequence of stem cell transplant, and nurses are urgently needed.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | March 29, 2023
The benefits of mindfulness meditation are numerous and far-reaching. But can they help HSCT recipients with GVHD?
Dustin SamplesGVHD | March 29, 2023
Certain species were predictive of not only the occurrence of GVHD, but also the severity.
Dustin SamplesGVHD | March 29, 2023
Pruritus is considered a mild adverse event, but does it negatively affect quality of life?
Dustin SamplesLymphoma | February 15, 2023
A case series demonstrated the effectiveness of a novel trio for pediatric plasmacytic PTLD.
Dustin SamplesLeukemia | January 17, 2023
Adolescents and young adults face different challenges than older survivors of ALL. Can technology improve these challenges?
Advertisement
Advertisement
Advertisement